News

Casgevy improved quality of life for severe SCD patients in trial

People with severe sickle cell disease (SCD) have reported significant improvements in their quality of life after receiving the approved gene-editing therapy Casgevy (exagamglogene autotemcel). That’s according to a new analysis of data from patients involved in a clinical trial that had tested the SCD treatment in individuals…